by Alison Bass | Apr 17, 2008 | Uncategorized
An article in The New York Times a few days ago about Vioxx almost makes it sound as if the ghostwriting of new drug studies by pharmaceutical companies is a new and relatively unknown practice. In fact, the ghost-writing of research by pharmaceutical companies eager...
